Thyroiditis

Barinthus Bio Presents Interim Data from Phase 2b HBV003 Trial and Phase 2a AB-729-202 Trial in Collaboration with Arbutus Biopharma in Chronic HBV Patients at AASLD

Retrieved on: 
Thursday, November 9, 2023
Group 3, Hepatology, Safety, Immune system, Thyroiditis, RNA interference, AASLD, Risk, MVA, NUC, Patient, HBV, Clinical trial, Non-cirrhotic portal fibrosis, Liver, SOC, Autoimmune thyroiditis, CHB, Cancer, Nivolumab, Hepatitis, Group 2, Autoimmunity, Thyroid disease, Șaeș, Vaccine, Pharmaceutical industry, HBsAg

Alongside this, a late-breaking poster presentation with interim data from patients with chronic hepatitis B (CHB) from the Phase 2a AB-729-202 trial combining Arbutus Biopharma Corporation’s (NASDAQ: ABUS) RNAi therapeutic candidate, imdusiran (AB-729), with Barinthus Bio’s T cell stimulating immunotherapeutic candidate, VTP-300, and SoC NUC therapy.

Key Points: 
  • Alongside this, a late-breaking poster presentation with interim data from patients with chronic hepatitis B (CHB) from the Phase 2a AB-729-202 trial combining Arbutus Biopharma Corporation’s (NASDAQ: ABUS) RNAi therapeutic candidate, imdusiran (AB-729), with Barinthus Bio’s T cell stimulating immunotherapeutic candidate, VTP-300, and SoC NUC therapy.
  • Barinthus Bio is a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer.
  • Preliminary immunology data suggests HBV-specific T cell IFN-γ production was enhanced in patients receiving imdusiran plus VTP-300 compared to placebo.
  • Dr. Karen Sims, Chief Medical Officer of Arbutus Biopharma, commented, “Imdusiran consistently delivers compelling efficacy and safety data in multiple Phase 2a populations and combinations.

Global Medical Tourism Market Report 2023: Sector is Expected to Reach $337 Billion by 2028 at a CAGR of 23% - ResearchAndMarkets.com

Retrieved on: 
Monday, May 22, 2023
Other Travel, Health, Travel, Other Health, Insurance, Surgeon, Obesity, Prevalence, Diabetes, Medical tourism, Arthritis, Anxiety, COVID-19, Cancer, Breast, Brain, Tobacco, Prostate, Lung, Dentist, Nursing, Beauty, Hospital, Thyroiditis, Patient, Blood, Dental care, United States Secretary of Labor, Kidney, Growth, Diagnosis, Health insurance, Dentistry, Tourism

Furthermore, as it offers top-quality medical assistance from expert surgeons, the demand for medical tourism is increasing around the world.

Key Points: 
  • Furthermore, as it offers top-quality medical assistance from expert surgeons, the demand for medical tourism is increasing around the world.
  • What is the expected growth rate of the global medical tourism market during 2023-2028?
  • What are the key regions in the global medical tourism market?
  • 7. Who are the key players/companies in the global medical tourism market?

MyMD Pharmaceuticals® Announces Upcoming Presentation of Late-Breaking Data for MYMD-1® at the 2022 British Society for Immunology (BSI) Congress

Retrieved on: 
Thursday, November 17, 2022
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Clinical Trials, Other Health, FDA, Warfarin necrosis, Anxiety, Chronic pain, British Society for Immunology, CB2, CAIA, Rheumatoid arthritis, Thyroiditis, Sarcopenia, Patient, Ageing, Pharmacology, RA, Human, Inflammation, CNS, BSI, Safety, MS, Immune system, Degenerative disease, Society, Arthritis, Frailty, Annual report, Congress, Central nervous system, Multiple sclerosis, COVID-19, Seizure, TNF, Genta (company), Pharmaceutical industry, CBD

MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (MyMD or the Company), a clinical stage biopharmaceutical company developing groundbreaking therapies for the treatment of serious and debilitating autoimmune and inflammatory diseases, has been invited to present late-breaking data at the 2022 British Society for Immunology (BSI) Congress in Liverpool, England.

Key Points: 
  • MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (MyMD or the Company), a clinical stage biopharmaceutical company developing groundbreaking therapies for the treatment of serious and debilitating autoimmune and inflammatory diseases, has been invited to present late-breaking data at the 2022 British Society for Immunology (BSI) Congress in Liverpool, England.
  • We believe strongly in the potential of MYMD-1 as a next-generation TNF- inhibitor.
  • MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD), is a clinical stage biopharma company developing groundbreaking therapies for the treatment of serious and debilitating autoimmune and inflammatory diseases.
  • Forward-looking statements speak only as of the date they are made and none of MyMD nor its affiliates assume any duty to update forward-looking statements.

MyMD Pharmaceuticals Announces Publication of Phase 1 Data for oral TNF-alpha Inhibitor MYMD-1® in Peer-Reviewed Journal Drug Research

Retrieved on: 
Monday, November 14, 2022
Science, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Clinical Trials, FDA, Warfarin necrosis, Anxiety, Chronic pain, CB2, Rheumatoid arthritis, Thyroiditis, Sarcopenia, Patient, Ageing, RA, Inflammation, CNS, Safety, MS, Degenerative disease, Immune system, Frailty, Drug development, Central nervous system, Multiple sclerosis, COVID-19, Seizure, Infection, TNF, Pharmaceutical industry, CBD

MYMD-1 is an oral next-generation TNF- inhibitor with the potential to transform the way that TNF- based autoimmune diseases are treated.

Key Points: 
  • MYMD-1 is an oral next-generation TNF- inhibitor with the potential to transform the way that TNF- based autoimmune diseases are treated.
  • Its ease of oral dosing is a significant differentiator compared to currently available TNF- inhibitors, all of which require delivery by injection or infusion.
  • In addition, it has not been shown to cause serious side effects common with traditional immunosuppressive therapies that treat inflammation.
  • MYMD-1 is currently being evaluated in Phase 2 studies for sarcopenia/frailty, a result of the aging process, with data expected in 4Q 2022.

Equillium Announces Initiation of Phase 2 study of EQ101 A First-in-Class Multi-Cytokine Inhibitor of IL-2, IL-9 and IL-15 Targeting Alopecia Areata

Retrieved on: 
Thursday, November 10, 2022
Biotechnology, Pharmaceutical, Health, Clinical Trials, Private Securities Litigation Reform Act, Head, Forward-looking statement, Prevalence, Adult, Alopecia totalis, Risk, University, IL-9, Depression, Nasdaq, Peptide, Cytokine, EDGAR, World Congress on Communication for Development, Anxiety, Thyroiditis, MCP, Incidence, Drug development, Face, SEC, Man, Alopecia areata, Safety, Dermatology, Degenerative disease, Hair loss, Alopecia universalis, Autoimmunity, Biomarker, Disease, JAK, Vitiligo, Patient, Immune system, 2009 Davis Cup, Woman, Therapy, Scalp, CTCL, Inflammation, Congress, Itolizumab, Trial of the century, Pharmaceutical industry, Vaccine, AA, Medicine

We believe this study will benefit from strong enrollment support and look forward to presenting data from this study next year.

Key Points: 
  • We believe this study will benefit from strong enrollment support and look forward to presenting data from this study next year.
  • Alopecia areata is one of the most common auto-immune diseases in man with a lifetime risk of two percent.
  • Equillium is currently enrolling patients in a Phase 2 proof-of-concept study of EQ101 for patients with alopecia areata.
  • Equillium is currently enrolling patients in a Phase 1 study of EQ102, including healthy volunteers and celiac disease patients.

EMD Serono to Highlight Data at ESMO 2022 with Potential for Transformative Impact on Cancer Patients

Retrieved on: 
Wednesday, September 7, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Fatigue, UC, Hepatotoxicity, Liver, Pfizer, Pleural effusion, Thyroiditis, Grade 3, Maintenance, Hypothyroidism, TEN, Breathe Me, PD-1, Grade 2, Photophobia, Pulmonary embolism, PD-L1, Nausea, Patient, Avelumab, Field line, Stevens–Johnson syndrome, Incidence, Eosinophilia, Pneumonitis, Headache, Insulin, FDA, Diabetes, Hyperthyroidism, Creatinine, Diarrhea, Hyperglycemia, Kidney, Erythroderma, Pneumonia, AST, Hepatitis, Colitis, Rash, Hypophysitis, MCC, Lists of diseases, Fourth grade, Endocrinology, Hypopituitarism, Dermatitis, Degenerative disease, Prednisone, Neoplasm, HIV disease progression rates, RCC, DRESS, Brain Quest Grades 3 & 4, SJS, Infection, ALT, Edema, Merck Group, Drug, Adrenal insufficiency, Diabetic ketoacidosis, Vaccine, Pharmaceutical industry, Cytomegalovirus, Angela Merkel

Consider administration of other systemic immunosuppressants in patients whose immune-mediated adverse reactions are not controlled with corticosteroid therapy.

Key Points: 
  • Consider administration of other systemic immunosuppressants in patients whose immune-mediated adverse reactions are not controlled with corticosteroid therapy.
  • Immune-mediated pneumonitis occurred in 1.2% (21/1738) of patients, including fatal (0.1%), Grade 4 (0.1%), Grade 3 (0.3%) and Grade 2 (0.6%) adverse reactions.
  • Immune-mediated colitis occurred in 1.5% (26/1738) of patients, including Grade 3 (0.4%) and Grade 2 (0.7%) adverse reactions.
  • Immune-mediated adrenal insufficiency occurred in 0.5% (8/1738) of patients, including Grade 3 (0.1%) and Grade 2 (0.3%) adverse reactions.

MyMD Pharmaceuticals Receives Grant From European Patent Office for Supera-CBD™ Compound

Retrieved on: 
Tuesday, August 30, 2022
Biotechnology, FDA, Alternative Medicine, Health, Cannabis, Consumer, Pharmaceutical, Other Science, Research, Managed Care, Natural Resources, Science, Seniors, Clinical Trials, Inflammation, Chronic pain, COVID-19, Pain, Pharmacokinetics, Cannabidiol, Degenerative disease, Central nervous system, Autoimmunity, Ageing, Disease, Multiple sclerosis, Anxiety, CB2, Opposition procedure before the European Patent Office, Frailty, Patent, Traffic barrier, TNF, Intention, Nasdaq, FDA, Immune system, Company, News, Warfarin necrosis, Genta (company), MS, European Patent Convention, Sarcopenia, Epilepsy, Thyroiditis, Annual report, CNS, Forward-looking statement, Longevity, Pharmaceutical industry, CBD

MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (MyMD), a clinical stage pharmaceutical company committed to developing novel therapies for age-related diseases, autoimmune and inflammatory conditions, announced today that it received a decision to grant from the European Patent Office in its application no.

Key Points: 
  • MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (MyMD), a clinical stage pharmaceutical company committed to developing novel therapies for age-related diseases, autoimmune and inflammatory conditions, announced today that it received a decision to grant from the European Patent Office in its application no.
  • The allowed claims cover MyMDs Supera-CBD compound as a new molecular entity and pharmaceutical formulations containing the compound.
  • This news, along with the ongoing clinical development of lead compound, MYMD-1, demonstrates the continued progress MyMD has made this year in advancing these two products.
  • The upcoming patent grant adds to the companys growing portfolio that already includes patents in the US, Australia, Canada, Israel, and South Korea for Supera-CBD and its therapeutic uses.

Professional Golfer Aza Muñoz Returns to LPGA Tour with New Solution for Treating Her Hypothyroidism

Retrieved on: 
Wednesday, August 24, 2022
Sports, General Sports, Alternative Medicine, Managed Care, Other Health, Health, Seniors, Pharmaceutical, Golf, Hispanic, Consumer, Muscle weakness, Insurance, Rash, Thyroiditis, Myocardial infarction, Breathe Me, Absorption, Irritability, Glycerol, Risk, Hypothyroidism, Levothyroxine, Patient, Diabetes, Cardiovascular disease, Menstruation, Obesity, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Appetite, Food, Hashimoto's thyroiditis, Headache, Insomnia, Heat intolerance, Tremor, Weight gain, FDA, Weight loss, THE, Social media, Partnership, Tablet, Spasm, Diarrhea, Stiff-person syndrome, Lists of diseases, Thyroid hormones, Pharmacy, Nervous, Diet, Multimedia, Water, Plasma protein binding, Â, Aza, LPGA, Health, Atrial fibrillation, IBSA, Hyperthyroidism, LPGA Tour Championship, Golf, McMillan, Arrhythmia, Diagnosis, CONTROL, Excipient, Common, Lethargy, Adrenal insufficiency, Public relations, Pharmaceutical industry, Meat

Professional golfer Azahara (Aza) Muoz will return to the LPGA Tour this fall as a new mom and as the new spokesperson for Tirosint-SOL (levothyroxine sodium) solution .

Key Points: 
  • Professional golfer Azahara (Aza) Muoz will return to the LPGA Tour this fall as a new mom and as the new spokesperson for Tirosint-SOL (levothyroxine sodium) solution .
  • My body ached, and practicing golf was so tough because I was always tired, said Muoz.
  • She tried to treat her condition using conventional thyroid medicine, but she still struggled with the symptoms of hypothyroidism.
  • We wish Aza the best of luck and health as she returns to the Tour!

Data Showing MyMD Pharmaceuticals’ MYMD-1® May Extend Life and Improve Health Published in the Journal of Gerontology: Biological Sciences

Retrieved on: 
Wednesday, August 3, 2022
FDA, Health, Clinical Trials, Research, Pharmaceutical, Science, IL-6, Hospital, Autoimmunity, Mouse, COVID-19, Inflammation, TNF, MS, Annual report, The Journals of Gerontology, Life, Pathology, Epilepsy, Cox, Disability, Degenerative disease, Frailty, Company, Chronic pain, MPH, CNS, Nasdaq, Biomarker, Ageing, FDA, Maintenance, BioMaPS Institute for Quantitative Biology, Disease, Metformin, Journal, Thyroiditis, Risk, BMJ Open, Pharmacokinetics, Vivo, Forward-looking statement, Longevity, Tumor necrosis factor, Genta (company), Serum, Intention, CMO, Sex, Death, Central nervous system, Multiple sclerosis, Immune system, Warfarin necrosis, Cytokine, Johns Hopkins School of Medicine, Traffic barrier, Cannabidiol, Sarcopenia, Pharmaceutical industry, Vaccine, CBD, MD

View the full release here: https://www.businesswire.com/news/home/20220803005056/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20220803005056/en/
    We are very excited that this important early data with our lead product MYMD-1 has been published in a prestigious medical journal, said Chris Chapman, MD, President, Director, and CMO of MyMD Pharmaceuticals.
  • Our ongoing Phase 2 study of MYMD-1 in sarcopenia/frailty, a result of a pathological aging process, is going well.
  • The companys scientific advisory board met recently and agreed to move to the next higher dose in the study.
  • In vivo, a longitudinal cohort of C57BL/6 mice, was randomized to receive either MYMD-1, high-dose rapamycin, or low-dose rapamycin plus metformin.

MyMD Pharmaceuticals to Collaborate with Bascom Palmer Eye Institute to Study MYMD-1 in Ophthalmic Conditions

Retrieved on: 
Tuesday, July 12, 2022
Science, Biotechnology, Research, Pharmaceutical, Optical, Health, Hospitals, Clinical Trials, Education, Autoimmunity, Annual report, Visual impairment, TNF, Thyroiditis, Central nervous system, MS, Quality of life, Frailty, Epilepsy, Bascom Palmer Eye Institute, Trauma, Incidence, Warfarin necrosis, U.S. News & World Report, Company, Multiple sclerosis, Doximity, Nasdaq, Degenerative disease, Forward-looking statement, FACS, CNS, Partnership, Disease, Chronic pain, Ageing, JAMA Ophthalmology, TON, Inflammation, Sarcopenia, COVID-19, Health, Longevity, Department, FDA, University, MTA, Severe cognitive impairment, Optic nerve, Bascom, Intention, History, Physician, Cannabidiol, Traffic barrier, Head, Research, News, Immune system, Genta (company), Pharmaceutical industry, Ophthalmology, CBD

The project is fully funded by Bascom Palmer Eye Institute.

Key Points: 
  • The project is fully funded by Bascom Palmer Eye Institute.
  • Following this initial pre-clinical study, the potential exists to collaborate with Bascom Palmer on large patient studies in the future, Dr. Chapman continued.
  • Bascom Palmer Eye Institute serves as the Department of Ophthalmology for the University of Miami Miller School of Medicine in Miami, Florida.
  • Bascom Palmer Eye Institute is ranked the #1 eye hospital in the United States by U.S. News & World Report, an honor it has received 20 times.